Compass Therapeutics (CMPX) EBITDA Margin (2024)
Compass Therapeutics recorded quarterly EBITDA Margin of 1538.47% in Q2 2024.
Compass Therapeutics' EBITDA Margin history runs 1 years deep, the most recent figure standing at 1538.47% for Q2 2024.
- In Q2 2024, EBITDA Margin changed N/A year-over-year to 1538.47%; the TTM figure through Jun 2025 stood at 7262.24% (down 175329.0% YoY), while the FY2024 annual figure was 5788.47%, changed N/A from the prior year.
- EBITDA Margin came in at 1538.47% for Q2 2024 at Compass Therapeutics.
- In the past five years, EBITDA Margin ranged from a high of 1538.47% in Q2 2024 to a low of 1538.47% in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1,538.47% |